• Mashup Score: 0
    The influence of sex hormones on musculoskeletal pain and osteoarthritis - 1 year(s) ago

    The association of female sex with certain rheumatic symptoms and diseases is now indisputable. Some of the most striking examples of this association occur in individuals with musculoskeletal pain and osteoarthritis, in whom sex-dependent changes in incidence and prevalence of disease are seen throughout the lifecourse. Joint and muscle pain are some of the most common symptoms of menopause, and…

    Source: The Lancet Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of TheLancetRheum
      TheLancetRheum

      ICYMI, in our April issue—@malvikagulati_1 and colleagues review what we know about the influence of #sex hormones on musculoskeletal #pain and #osteoarthritis https://t.co/Mxjn6UASFq https://t.co/9qmVobeRwK

  • Mashup Score: 0
    Patient-led research in rheumatology: the way forward? - 1 year(s) ago

    We read with interest the comment by Su-Ann Yeoh and colleagues1 discussing patient and public involvement in research. Both The Lancet2 and the BMJ3 have advocated for patient-led research, which is research that is conceived and facilitated by individuals with lived experience of disease, to bridge the gap between clinician and patient priorities. Patient-led research in rheumatology is…

    Source: The Lancet Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of TheLancetRheum
      TheLancetRheum

      Correspondence in our April issue—@danielleberko @IlanaAckerman & @RachelleBuchbin advocate for better patient-led rheumatology research, in response to the Australian Government's recent patient-driven national strategy for arthritis research https://t.co/ArtrDIiyeI https://t.co/IfZQkuy554

  • Mashup Score: 0
    Is it Autumn for colchicine and osteoarthritis? - 1 year(s) ago

    Colchicine is an ancient drug, derived from plants of the Colchicum variety (or Autumn Crocus). Mentioned in the Ancient Egyptian Ebers papyrus, colchicine was purified by the 18th century and has been in regular use by physicians ever since; it was finally licensed by the US Food and Drug Administration in 2009 for the prophylaxis and treatment of gout.1 Low doses of colchicine (0·5 mg two to…

    Source: The Lancet Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of TheLancetRheum
      TheLancetRheum

      @AnnaDossing Is it Autumn for colchicine and osteoarthritis? Linked Comment by Fiona E Watt @ImperialImmuno https://t.co/0ii6pNl14Z https://t.co/X09FBVk3ct

  • Mashup Score: 1
    Research in Brief - 1 year(s) ago

    The efficacy of baricitinib, a selective inhibitor of Janus kinase 1 and 2, in systemic lupus erythematosus (SLE) was inconclusive following two identically designed multicentre, double-blind, randomised, phase 3 trials (SLE-BRAVE-I and SLE-BRAVE-II). In both trials, adult patients with active SLE receiving stable background therapy were randomly assigned (1:1:1) to receive baricitinib 4 mg,…

    Source: The Lancet Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of TheLancetRheum
      TheLancetRheum

      April Research in Brief featuring #SLE, #systemicsclerosis, #COVID19 and more! https://t.co/UpWldtw1ig https://t.co/X2p0K3c3eA

  • Mashup Score: 1
    Patient–researcher co-presentation of research results to people living with systemic sclerosis - 1 year(s) ago

    Many people with rheumatic diseases participate in research, despite the burdens involved, to contribute to the wellbeing of others with rheumatic diseases, and most want to learn about the research results.1 Sharing results with patients generally, beyond study participants, might help to build trust in research, increase the likelihood of research participation, and contribute to supporting…

    Source: The Lancet Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of TheLancetRheum
      TheLancetRheum

      New Correspondence in our April issue—Vanessa Cook and colleagues discuss an initiative for patient–researcher co-presentation of research results to people living with #systemicsclerosis https://t.co/D7kdSRxJDr @SclerodermaCAN @scleroderma_sso @LadyDavisJGH https://t.co/UgSksUYalx

  • Mashup Score: 0
    Kimberly Templeton: creative change maker - 1 year(s) ago

    Kimberly Templeton describes herself as having two personas, one driven by a desire to affect change and the other by her creativity. Both, however, come together in her role as an orthopaedic surgeon. Templeton is Professor and Vice Chair in the Orthopaedic Surgery Department, Director of the Orthopaedic Surgery Residency Program, and Associate Dean for Continuing Medical Education at the…

    Source: The Lancet Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of TheLancetRheum
      TheLancetRheum

      NEW PROFILE—Kimberly Templeton: creative change maker https://t.co/XmsDZAvLgB @KimTempleton3 @AMWADoctors @KUMedCenter https://t.co/X259zlAWtk

  • Mashup Score: 0
    Reconciling immunotherapy and autoimmunity: not for the faint of heart - 1 year(s) ago

    Immune checkpoint inhibitors, a class of immunotherapy, have revolutionised cancer therapy. Nearly half of all patients with metastatic cancer are eligible for immune checkpoint inhibitor treatment, and use for patients with early-stage cancers in the adjuvant setting is rapidly increasing.1 Immune checkpoint inhibitors exert anti-tumour effects by blocking immune checkpoints, which typically…

    Source: The Lancet Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of TheLancetRheum
      TheLancetRheum

      @Deepakarao @jeffsparks Reconciling immunotherapy and autoimmunity: not for the faint of heart Linked Comment by Carrie Ye @UAlberta_DoM https://t.co/ClIEOtlVma https://t.co/nHryWzCJpd

Load More